In SUSTAIN-7, nausea or vomiting occurred similarly for semaglutide 0.5 mg and 1 mg and dulaglutide 1.5 mg (4348%), yet less frequent with dulaglutide 0.75 mg (33%) (29)
The starting dose was 2.5 mg and was increased by 2.5 mg every 4 weeks until hitting the maximum dosage of 10 mg or 15 mg
For more information about these drugs, including details about their uses, see the in-depth overviews on Ozempic and Mounjaro
doi:10.1016/0014-5793(88)80509-x
Several alternative therapeutic strategies have been investigated, including protein kinase C inhibitors [10], darbepoetin alfa [11], endothelin receptor antagonists (ERAs) [12], direct renin inhibitors [13], nuclear factor erythroid 2-related factor 2 activators [14], and combination of ACE inhibitor and ARB [15]